Extending gains for the second straight session, the BSE Sensex gained as much as 916 points, or 1.15%, to 80,393 during the session so far. In a similar trend, the NSE Nifty surged 274 points, or ...

How will India’s leading drugmaker handle legal setbacks, volatile market trends, and competition in generics and specialty products?

Swiggy aims to raise a total of ₹11,327.43 crore from this IPO, marking it as the second-largest IPO in India this year after ...

India's Mankind Pharma reported a better-than-expected second-quarter profit on Tuesday, driven by strong demand for its drugs to treat long-term illnesses, such as diabetes and cardiovascular ...

Shares of Sun Pharmaceutical Industries Ltd. 524715 inched down 0.31% to 1,803.25 Indian rupees Tuesday, on what proved to be ...

The stock was up 11% to $11.73 on Monday. Shares have jumped 37% over the past 12 months. The pharmaceutical company said the proceeds of the royalty financing deal will be used t ...

This decision delays Sun Pharma's planned US launch of the product, which could be deferred for several months if the company ...

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

Indian generic injectables maker Gland Pharma reported a drop in second-quarter profit on Monday, hurt by lower sales in its Europe business and temporary production issues at its French unit Cenexi.

After a US Court blocked the launch of Leqselvi, a drug used to treat severe alopecia areata, shares of Sun Pharma plunged ...

Thirty out of the 41 analysts tracking the company have a 'buy' rating on the stock, seven suggest a 'hold' and four have a ...